A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Renal Function and Subjects With Impaired Renal Function

Trial Profile

A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Renal Function and Subjects With Impaired Renal Function

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Dabrafenib (Primary)
  • Indications Brain metastases; Cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 03 Jan 2017 Planned End Date changed from 1 Apr 2018 to 1 Jul 2018.
    • 03 Jan 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jul 2018.
    • 03 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top